Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 2/20 | 0.31 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16624822 | 0.86 | HTT (0.36) | AKT1P2RY12ITGB3ITGA2BAKT2 | |
| SCHEMBL16773363 | 0.86 | P2RY12 (0.32) | AKT1P2RY12ITGB3ITGA2BAKT2 | |
| SCHEMBL16784372 | 0.78 | KIT (0.47) | — | |
| SCHEMBL16773487 | 0.75 | MTNR1B (0.32) | AKT1P2RY12AKT2AKT3 | |
| SCHEMBL16773364 | 0.72 | AURKA (0.41) | AKT1P2RY12AKT2AKT3 | |
| SCHEMBL16773148 | 0.72 | AURKA (0.30) | — | |
| SCHEMBL17634059 | 0.70 | AKT1 (0.36) | AKT1P2RY12AKT2AKT3 | |
| SCHEMBL17634058 | 0.70 | AKT1 (0.36) | AKT1P2RY12AKT2AKT3 | |
| SCHEMBL16784431 | 0.68 | KIT (0.46) | — | |
| SCHEMBL18950223 | 0.66 | KIT (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790190-B2 | Process for making hydroxylated cyclopentylpyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9676730-B2 | Process for making hydroxylated cyclopentylpyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160318877-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. (US) | 2016-11-03 | — | — | US | disclosed |
| US-9416110-B2 | Process for making hydroxylated cyclopentylpyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150152067-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | GENENTECH, INC. | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152067-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | DPYD, DHPS, TYMP | AKT1 2391/4885P2RY12 1528/4885ITGB3 4647/4885 |
| US-20160318877-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | DPYD, DHPS, TYMP | AKT1 2391/4885P2RY12 1528/4885ITGB3 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.